Original researchEfficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: A pilot study
References (28)
- et al.
Rheumatoid arthritis
Lancet.
(2001) - et al.
Long-term outcome of treating rheumatoid arthritis: Results after 20 years
Lancet
(1987) - et al.
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis
Lancet.
(1994) - et al.
Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised Phase III trial
Lancet.
(1999) Epidemiology of rheumatic diseases
Rheumatology (Oxford)
(2000)- et al.
Taking mortality in rheumatoid arthritis seriously—predictive markers, socio-economic status and comorbidity
J Rheumatol.
(1986) - et al.
Disappointing longterm results with disease modifying antirheumatic drugs. A practice based study
J Rheumatol.
(1999) Conventional DMARD options for patients with a suboptimal response to methotrexate
J Rheumatol Suppl
(2001)- et al.
Cytokine pathways and joint inflammation in rheumatoid arthritis
N Engl J Med.
(2001) - et al.
Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
N Engl J Med.
(1997)
Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: The initial results of five trials
Ann Rheum Dis.
(2002)
Preliminary results of early clinical trials with the fully human anti-TNF-alpha monoclonal antibody D2E7
Ann Rheum Dis.
(1999)
Update on D2E7: A fully human anti-tumour necrosis factor alpha monoclonal antibody
Ann Rheum Dis.
(2000)
Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis
Ann Rheum Dis.
(2001)
Cited by (274)
Quantifying the Effect of Methotrexate on Adalimumab Response in Psoriasis by Pharmacokinetic–Pharmacodynamic Modeling
2024, Journal of Investigative DermatologyModeling the subcutaneous pharmacokinetics of antibodies co-administered with rHuPH20
2024, Clinical and Translational ScienceFormation and clearance of TNF–TNF inhibitor complexes during TNF inhibitor treatment
2024, British Journal of PharmacologyFactors Influencing Adalimumab Treatment Response in Patients with Rheumatoid Arthritis: The Future of Clinical Expertise
2023, Al-Rafidain Journal of Medical Sciences
Copyright © 2003 Published by Elsevier Inc.